NASDAQ:VXRT

Vaxart Stock News

Healthcare > Biotechnology

Buy VXRT

*Your capital is at risk

$0.519

-0.0111 (-2.09%)

At Close: Jun 23, 2026

Vaxart Announces Adjournment of Special Meeting of Stockholders

08:00am, Monday, 08'th Sep 2025

Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations an

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

04:30pm, Tuesday, 02'nd Sep 2025

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recomb

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

09:00am, Tuesday, 02'nd Sep 2025

Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Sto

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

09:30am, Thursday, 21'st Aug 2025

Urge Stockholders to Vote “AGAINST” Reverse Stock Split at Upcoming Special Meeting Call for Accountability Given Board's Pattern of Disregarding Stockholders' Will and Value-Destructive Capital A

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

09:01pm, Wednesday, 13'th Aug 2025

Vaxart, Inc. (OTC:VXRT) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Edward B. Berg - Senior VP & General Counsel James F.

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

06:26pm, Wednesday, 13'th Aug 2025

VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09.

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

05:25pm, Wednesday, 13'th Aug 2025

Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, joining multiple biotech companies that have lost government funding for their

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

04:01pm, Thursday, 24'th Jul 2025

- Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Pane

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

07:00am, Tuesday, 08'th Jul 2025

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQ

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

04:52pm, Friday, 13'th Jun 2025

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recomb

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

07:30am, Wednesday, 11'th Jun 2025

- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constru

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by